Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | UNG | P13051 | 2/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7010646 | 0.85 | PLA2G7 (0.39) | DHFRGPR84PLA2G7CETP | |
| SCHEMBL7012920 | 0.73 | PLA2G7 (0.44) | PLA2G7 | |
| SCHEMBL7011218 | 0.73 | PLA2G7 (0.44) | PLA2G7 | |
| SCHEMBL11734497 | 0.67 | SIRT2 (0.37) | KMT2A | |
| SCHEMBL7829766 | 0.64 | HTR1A (0.48) | DHFRPPARGPPARAKMT2ALPL | |
| SCHEMBL27550693 | 0.62 | DHFR (0.52) | DHFRPPARGPPARALPLLIPG | |
| SCHEMBL7011376 | 0.62 | PLA2G7 (0.46) | PLA2G7KMT2A | |
| SCHEMBL29742685 | 0.61 | LPL (0.67) | PPARGPPARALPLLIPG | |
| SCHEMBL4032533 | 0.61 | LPL (0.67) | PPARGPPARALPLLIPG | |
| SCHEMBL5249436 | 0.61 | LPL (0.67) | PPARGPPARALPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | DHFR 41/4885GPR84 887/4885PLA2G7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.